National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Daratumumab (Darzalex®) for use in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

NCPE Assessment Process Complete
Rapid review commissioned 09/10/17
Rapid review completed 27/11/17
Rapid Review Outcome A full pharmacoeconomic evaluation is recommended.
Full pharmacoeconomic assessment commissioned by HSE 29/11/2017
Pre-submission consultation with Applicant 23/01/2018
Submission received from Applicant 21/09/2018
Preliminary review sent to Applicant 30/11/2018
NCPE assessment re-commenced 20/12/2018
Factual accuracy sent to Applicant 05/02/2019
NCPE assessment re-commenced 13/02/2019
NCPE assessment completed 15/03/2019
NCPE assessment outcome

The NCPE recommends that daratumumab combination (Darzalex®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.
This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Summary